3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
2
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
Vorinostat
3
Azacitidine
3
venetoclax
2
trametinib
2
ruxolitinib
2
pertuzumab
2
palbociclib
2
olaparib
2
durvalumab
2
dabrafenib
2
copanlisib
2
aflibercept
2
abiraterone
2
Sunitinib
2
Specimen Handling
2
Sirolimus
2
Nivolumab
2
Immunoglobulin G
2
HhAntag691
2
Doxorubicin
2
Disulfides
2
Dasatinib
2
Cyclophosphamide
2
Biopsy
2
Afatinib
2
Ado-Trastuzumab Emtansine
2
2C4 antibody
2
ulixertinib
1
tremelimumab
1
trastuzumab biosimilar HLX02
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Inosine Monophosphate
×
Lymphoid
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled